Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 5 Melanoma 3 Uveal Melanoma 2 Neoplasms 2 Lymphoma, B-Cell 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Sarcopenia 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Lymphoma, Follicular 1 Gastrointestinal Stromal Tumors 1 Esophageal Squamous Cell Carcinoma 1 Efficacy, Team 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Desmoplastic Small Round Cell Tumor 1 Colonic Neoplasms 1 Chondrosarcoma 1 Carcinoma, Renal Cell 1 Bone Neoplasms 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 1 Nivolumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Efficacy, Team × Nivolumab × Clear all

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Efficacy, Team

Data powered by HemOnc (CC BY 4.0) Colophon ⚡